Lung Cancer

Top Story

Biocept, UT Southwestern to study liquid biopsy platform in ALK-positive non-small cell lung cancer

August 18, 2017

Biocept Inc. and University of Texas Southwestern Medical Center entered a clinical study agreement to evaluate the clinical utility of Biocept’s Target Selector platform for patients with ALK-positive non-small cell lung cancer.

The liquid biopsy platform is designed to capture and analyze tumor-associated molecular markers in both circulating tumor cells and circulating tumor DNA to identify cancer mutations and alterations that can inform physicians about a patient's disease and potential therapeutic options.

In the Journals Plus

Liquid biopsy offers option for EGFR testing without lung tumor tissue

August 15, 2017
Blood assays identified EGFR mutations in patients with advanced non-small cell lung cancer with insufficient tumor biopsies, according to a prospective analysis…
In the Journals Plus

Older patients with cancer may burden caregivers by overestimating physical abilities

August 14, 2017
Older patients with cancer often reported having better physical function, mental health and social support than their caregivers’ assessments, according to study…
In the Journals Plus

ASCO updates guideline on systemic therapy for non-small cell lung cancer

August 14, 2017
An updated ASCO clinical practice guideline clarifies the appropriate use of immunotherapy and provides new recommendations on the use of targeted therapy for patients…
More Headlines »
CME Video

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Video
Meeting News

VIDEO: Gefitinib may ‘change the paradigm’ to treat lung cancer

August 10, 2017
More »
Resource Centers

CME

Immuno-Oncology Forum: Focus on Non-Small Cell Lung Cancer

This activity is supported by educational grants from Bristol-Myers Squibb; Genentech, Inc.; and Merck & Co., Inc.

Lung cancer accounts for 27% of all cancer deaths in the United States, making it the leading cause of cancer…
More »
Advertisement
Advertisement